![step up 4 online pl step up 4 online pl](https://spokeo.pl/storage/article/YQ6d6r1Ma5uWh8L0c2RC3Pc1pH8OK7TVN13EtzlI.jpeg)
![step up 4 online pl step up 4 online pl](https://fwcdn.pl/fpo/79/90/477990/7330789.6.jpg)
Dr Teague serves on advisory boards for Aviragen and Genentech/Novartis. Dr Szefler has no financial interests to disclose. Dr Phipatanakul is a consultant for TEVA, Regeneron/Sanofi, Genentech/Novartis, and GlaxoSmithKline. Dr Murphy has received consultancy and speaker fees and has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Genentech, Greer, Meda, Merck, Mylan, Novartis, and Teva. Dr Jackson serves on advisory boards for Commense and Boehringer Ingelheim and has received lecture fees from Merck and a research grant from GlaxoSmithKline. Dr Farrar has no financial interests to disclose. Dr Bacharier has received consulting and/or lecture fees from Aerocrine, AstraZeneca, Cephalon, GlaxoSmithKline, Genentech/Novartis, TEVA, Merck, and Boehringer Ingelheim serves on advisory boards for Merck, Sanofi, Vectura Group and Circassia serves on a data and safety monitoring board for DBV Technologies and reports honoraria for CME program development from WebMD/Medscape. The objective is to provide clinicians who treat children with asthma practical and clinically relevant recommendations for each step-up and each intervention, with the intent of helping practitioners better treat their pediatric patients with asthma, particularly those who do not always respond to recommended therapies.ĭisclosures: Dr Chipps serves as a consultant and a member of speakers' bureaus for AstraZeneca, Boehringer Ingelheim, Genentech/Novartis, Meda, and Merck. Development of this tool follows others in the Yardstick series, presenting patient profiles and step-up strategies based on current guidance documents, but modified according to newer data and the authors' combined clinical experience.
![step up 4 online pl step up 4 online pl](https://images-na.ssl-images-amazon.com/images/I/91HCzBBdvaL._RI_.jpg)
Step up 4 online pl how to#
The Pediatric Asthma Yardstick provides an in-depth assessment of when and how to step-up therapy for the child with not well or poorly controlled asthma. Furthermore, treatment is challenged by the 3 age groups of childhood-adolescence (12–18 years old), school age (6–11 years old), and young children (≤5 years old)-and what works for 1 age group might not be the best approach for another. Although tools are available to help children (and families) track and manage day-to-day symptoms, when and how to implement a longer-term step-up in care is less clear. However, for children with asthma, achieving control can be elusive. Current asthma guidelines recommend a control-based approach to management involving assessment of impairment and risk followed by implementation of treatment strategies individualized according to the patient's needs and preferences.